2 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOCompleted
We aim to study what the mean change in graft flow rate is when the cardiac output is increased with 10% and what the mean change in graft flow rate is, when the blood pressure is increased with 10% to enable further research to establish whether an…